The BioPharm Brief: Rare Disease, Trial Setbacks, and Oral Obesity

The FDA launches a new rare disease development initiative, BioNTech’s BNT113 misses a progression-free survival endpoint, and Viking Therapeutics begins phase 3 trials of its oral obesity candidate.